Bristol-Myers Squibb Co. (BMY) said it is commencing today, through its wholly owned subsidiary B&R Acquisition Co., a cash tender offer to buy all outstanding shares of common stock of Amylin Pharmaceuticals, Inc. (AMLN).
Bristol-Myers stated that upon the successful closing of the tender offer, stockholders of Amylin will get $31 in cash for each share of Amylin common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable withholding taxes. Subsequent to the purchase of shares in the tender offer, Amylin will become a subsidiary of Bristol-Myers.
The tender offer will expire at 5:00 PM on August 7, 2012, unless extended in accordance with the merger agreement and the applicable rules and regulations of the Securities and Exchange Commission.
For comments and feedback: editorial@rttnews.com